On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of its public offering. According to the announcement, the “reasonable best efforts” public offering involves participation from healthcare-focused institutional investors and certain officers and directors of … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Information on $4M Public Offering Pricing”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has appointed a biotech veteran to its board of directors. The company announced that Amy Mahery, a highly accomplished biopharmaceutical industry executive, will join the company’s board effective upon … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of Directors”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has completed enrollment in its global potentially pivotal study evaluating Berubicin. According to the announcement, the study has enrolled 247 patients across 46 clinical trial sites in the United States, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reaches Planned Enrollment Berubicin Study for the Treatment of GBM”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced a recommendation from the independent Data Safety Monitoring Board (“DSMB”) regarding Berubicin, the company’s investigational agent. According to the announcement, the DSMB recommends that CNS Pharmaceuticals’ ongoing global, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces DSMB Recommendation to Continue Pivotal GBM Study without Modification”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the company announced that 200 out of 243 expected patients had been enrolled in its ongoing study evaluating the effectiveness of Berubicin for recurrent glioblastoma (“GBM”), a highly aggressive and incurable … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluating Berubicin. According to the announcement, the data showed the comparability of the patient demographics in … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Updated Safety Data from Berubicin Study at SNO Annual Gathering”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its lead treatment candidates, Berubicin, with the public before the end of the year. Berubicin is … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting on its financial results for third quarter, the period ended Sept. 30, 2023; the company also noted upcoming milestones. Notable financial numbers from the report include net … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”). “The Texas-based company has clinical trial sites operating in the U.S., Italy, France, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month’s Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals CEO John Climaco is scheduled to participate in a live moderated webcast during the conference; … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference”

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered